Home » Agenda


Protein & Antibody World Congress 2023 Europe

London, United Kingdom

Monday 13th - Tuesday 14th November 2023

Paradigm Global Events is very pleased to welcome you to our upcoming PROTEIN AND ANTIBODY Wordl CONGRESS 2023 Europe For decades, protein engineering has been a powerful tool in biotechnology for generating vast numbers of useful enzymes for industrial applications. Protein engineering aims to harness the existing molecular- level knowledge of how biology functions and alter these functions to improve the useful value of biological systems. The adaptation of newer mutagenesis techniques and computational design tools have greatly aided the development of high throughput platforms, discovery of new target proteins, and refinement of protein and non-protein design and engineering.

Protein is considered in extensive area of therapeutic space from target enzymes through to engineered versions of naturally occurring human proteins. But the most interesting and rapid moving group of proteins are antibodies. This area has grown from early days of monoclonal antibodies to a field of many engineered by-products. Today, antibodies are being engineered into a range of different novel drug classes, from ADC that deliver highly potent chemotherapy agents to kill cancer cells to multivalent antibodies that bind different antigens simultaneously.

The Global Protein Engineering market size is expected to be worth around 9,329 Million USD by 2032 from 2,961 Million USD in 2022, growing at a CAGR of 13.60% during the forecast period from 2023 to 2032. (Market.us)

Various factors such as the increasing need for personalised medicines, evolution in biopharmaceuticals, and the increasing industrial application of proteins are several factors steering the demand for protein engineering. However, as protein engineering involves complex processes, the associated high development cost can pose a restrain to the widespread adoption. Protein modification especially in gene editing also requires ethical and safety considerations. Rigorous regulations and public
apprehension in regard to genetic modifications can present challenges to market growth.

We are gathering high caliber expert speakers to participate and share their knowledge and expertise through Keynotes, Presentations, and Panel discussions.

We look forward to welcoming you to the Decentralized Clinical Trials World Congress 2023 Europe.

Sincerely yours,

Jocelyn Raguindin
Conference Director
Paradigm Global Events


  • Addressing the challenges and exploring opportunities in Protein Engineering
  • Breakthroughs in Protein and Antibody technology
  • AI and Machine learning techniques for antibody engineering and discovery
  • Application of technological platforms for protein sequence alignments and high-throughput analysis
  • Examining the current biological and engineering challenges facing the biomanufacturing of antibodies
  • Docking optimization and protein flexibility for larger scale manufacturing
  • Construction of ADCs as targets for new drug development
  • Addressing challenges unique to Cell-based and Non-cell-based neutralizing antibody assays
  • Recent approaches in targeting the “Undruggable” proteins
  • Analysis of protein engineering designs of non-standard amino acids
  • Safety and efficacy of antibody therapeutics


Network with scientists, analysts, senior VPs, Heads, Directors and Managers of leading biopharmaceutical and biotech companies, diagnostics, government, CRO and Solution providers whose responsibilities includes;

• Antibody Drug Conjugates
• Protein Science
• Antibody Engineering
• Antibody Therapeutics
• Immunogenicity
• Process Development
• Protein Engineering
• Protein Characterization
• Downstream Processing
• High Throughput Protein Screening
• Antibody Discovery
• Protein Purification

  • Potential applications on cellular pathway alteration at the protein level: targeted protein sequestration, protein recruitment, protein degradation, and selective
    inhibition of binding interfaces
  • Biochemical, genetic, and technological challenges in genetic code engineering


  • Recent advances in computational/AI-based techniques for antibody engineering and discovery
  • AI methods relevant for antibody development
  • Computational antibody design procedures with emphasis to machine learning
  • Examining the current biological and engineering challenges facing the biomanufacturing of antibodies
  • Emerging technologies to reduce biomanufacturing challenges.
  • Innovations in process analytical technologies and single use technologies to improve current performance of mAb production processes.
  • Docking setup using the wrapper code approach to optimize the DOCK program for large-scale computation as well as docking analysis using variance and promiscuity
  • Relevance of Small angle X-ray scattering (SAXS) for quantifying conformational flexibility in proteins
  • Feasibility of MARS for the measurement of both protein purity-related and formulation-related PQAs
  • Potential to be a powerful methodology to improve the efficiency of biopharmaceutical development and manufacturing


  • Comprehensive overview of validated, forgotten and newly develop payloads with diverse procedures of action.
  • Key role of Payload Diversification in the field of future ADC development
  • Advantages of payloads and benefits of payload diversification
  • Evolution of Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) targets for cancer therapy
  • Use of scTRAIL and associated peptide linkers as promising strategy for antitumor therapeutics
  • Steps in the process of antibody discovery and development
  • Differences in developability analyses in discovery and development stages
  • Developability-related considerations and assessment at the discovery stage
  • Analysis and optimization of developability-related attributes
  • Carbohydrates as promising targets for vaccine development against infectious disease
  • Strategies on overcoming challenges carbohydrate-based vaccine design and development approaches targeting cancer and other diseases
  • How can general protein language models efficiently evolve human antibodies?
  • Could these models be applicable to evolving more unnatural, de novo designed proteins
  • Comparison to other sequence-based methods
  • Computational efficiency of this approach
  • Leveraging data beyond protein sequence information including protein structure information and binding affinity data to further improve the outcome
  • ADCs role in the new wave of investigational drug candidates in this field
  • Impact of ADCs on technology development using better linker/payload chemistry and improved processes


  • ADCs role in the new wave of investigational drug candidates in this field
  • Impact of ADCs on technology development using better linker/payload chemistry and improved processes
  • Validation testing and reporting strategies and tools
  • Influence of interfering factors known to cause false ADA positive signals.
  • Framework and a concise reporting structure for NAb assay validations.
  • The need for industry-wide alignment that will streamline the review process by regulatory agencies
  • Lactic acid bacteria as promising vectors of choice to deliver active molecules to mucosal tissues
  • Recent developments on surface-display technologies important for potential industrial applications of lactic acid bacteria
  • Recent development of drug discovery targeting “undruggable” proteins and their application in clinic.
  • Opportunities for undruggable targets in treatment of human diseases
  • Innovative approaches and cutting-edge technologies resulting in several approved drugs and emerging potent chemical entities
  • Key considerations that drive the chemical design of protein-based therapeutics
  • Well-established and emerging structural and chemical design strategies that have enabled paradigm shift in diseases treatment.
  • Areas that need further development to realize the full potential of these molecules
  • Review of the development of mRNA peptide display
  • How is this technology applied in Drug discovery?
  • Addressing the Challenges and future outlook
  • Implications of mesotrypsin up-regulation in cancer progression
  • Recognition of mesotrypsin’s unique capability on cleavage and inactivation of proteinaceous inhibitors for development of anticancer protein therapeutics
  • Overview of the many ways in which ligands can affect GPCR function.
  • How this information can be used to develop novel therapeutics against various GPCR targets.
  • Challenges and promising opportunities.
  • New innovative strategies and tools needed to design, develop, and pharmacologically characterize novel GPCR ligands with the aim of creating better
    and more specific drugs.
  • Therapeutic antibody development process overview
  • Key parameters influencing therapeutic antibody development.
  • Innovative tools and methods used to assess product purity and safety throughout therapeutic antibody development.
  • Importance of successfully demonstrating safety and efficacy of therapeutic antibodies for regulatory approval and market authorization
Scroll to Top